7.046
price up icon1.67%   0.116
 
loading
Kala Bio Inc stock is traded at $7.046, with a volume of 12,754. It is up +1.67% in the last 24 hours and down -23.58% over the past month. Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$6.93
Open:
$7.19
24h Volume:
12,754
Relative Volume:
0.21
Market Cap:
$40.58M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.565
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+6.11%
1M Performance:
-23.58%
6M Performance:
+19.63%
1Y Performance:
-3.87%
1-Day Range:
Value
$6.6625
$7.19
1-Week Range:
Value
$6.41
$7.19
52-Week Range:
Value
$4.21
$11.20

Kala Bio Inc Stock (KALA) Company Profile

Name
Name
Kala Bio Inc
Name
Phone
781-996-5252
Name
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Name
Employee
43
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
KALA's Discussions on Twitter

Compare KALA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KALA
Kala Bio Inc
7.06 40.58M 5.75M -38.96M -32.63M -12.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.58 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
688.28 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.75 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.40 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.82 27.34B 3.30B -501.07M 1.03B -2.1146

Kala Bio Inc Stock (KALA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-30-22 Downgrade JP Morgan Neutral → Underweight
Aug-06-21 Downgrade JP Morgan Overweight → Neutral
Sep-14-20 Downgrade Jefferies Buy → Hold
Jul-23-20 Initiated Northland Capital Outperform
Jun-01-20 Resumed Oppenheimer Outperform
May-27-20 Reiterated H.C. Wainwright Buy
Mar-09-20 Upgrade BofA/Merrill Neutral → Buy
Dec-17-19 Downgrade BofA/Merrill Buy → Neutral
Mar-14-19 Initiated Jefferies Buy
View All

Kala Bio Inc Stock (KALA) Latest News

pulisher
Feb 26, 2025

Kala Bio appoints new interim CEO amid leadership shuffle - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

What Will KALA BIO Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan

Feb 26, 2025
pulisher
Feb 26, 2025

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN

Feb 26, 2025
pulisher
Feb 19, 2025

Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha

Feb 19, 2025
pulisher
Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan

Feb 18, 2025
pulisher
Feb 18, 2025

KALA BIO's (KALA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Kala Bio Inc (NASDAQ: KALA) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register

Feb 17, 2025
pulisher
Feb 15, 2025

KALA BIO says CEO Mark Iwicki resigns - MSN

Feb 15, 2025
pulisher
Feb 13, 2025

Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Kala Bio announces CEO departure, appoints interim leader By Investing.com - Investing.com Australia

Feb 13, 2025
pulisher
Feb 12, 2025

Lee joins Lycia as CMO - BioCentury

Feb 12, 2025
pulisher
Feb 12, 2025

Kala Bio appoints new interim CEO amid leadership shuffle By Investing.com - Investing.com Australia

Feb 12, 2025
pulisher
Feb 12, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

Chefs' Warehouse, Aptose Biosciences, Electromed - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Stock Market Today: Dow Jones tumbles 400 points as US inflation surges to 3%, S&P 500 and Nasdaq also slide amid Fed rate cut concerns - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Stock Market Today: Dow Jones tumbles 400 points as US inflation surges to 3%, S&P 500 and Nasdaq also sli - The Economic Times

Feb 12, 2025
pulisher
Feb 12, 2025

Stock market news: Spire Global -52.49%, Atomera -38.61% among biggest losers during midday trading - Business Upturn

Feb 12, 2025
pulisher
Feb 12, 2025

Dow Drops More Than 400 Points After CPI Data - Schaeffers Research

Feb 12, 2025
pulisher
Feb 12, 2025

Kala Bio Chief Executive Mark Iwicki Resigns; Shares Fall -February 12, 2025 at 11:59 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Kala Bio tumbles after CEO resignation - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Stock market today: Spire Global -50.98%, KALA BIO -32.54% among biggest losers in early trading - Business Upturn

Feb 12, 2025
pulisher
Feb 12, 2025

Wall Street Today: Dow Jones drops 400 points as US Inflation rises 50 bps to 3% YoY, dimming hopes for Fed rate cuts - Mint

Feb 12, 2025
pulisher
Feb 12, 2025

KALA BIO, Inc. Announces Chief Executive Officer Changes -February 12, 2025 at 08:00 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Kala Bio announces CEO departure, appoints interim leader - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

KALA BIO Announces Chief Executive Officer Transition - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

Leadership Shake-Up at KALA BIO: New CEO Takes Helm Before Crucial Phase 2b Eye Treatment Results - StockTitan

Feb 12, 2025
pulisher
Feb 12, 2025

KALA BIO (NASDAQ:KALA) and Prothena (NASDAQ:PRTA) Financial Survey - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

Avis Budget CEO Joe Ferraro to Step Down, Brian Choi Named Successor - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

Katoro Gold announces general meeting and office move - MSN

Feb 11, 2025
pulisher
Feb 07, 2025

Kala Pharma Catches Investors' Eye, Stock Hits New High - RTTNews

Feb 07, 2025
pulisher
Feb 05, 2025

Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Rises By 19.1% - MarketBeat

Feb 05, 2025
pulisher
Feb 01, 2025

Guardian Revival Names CEO - MSN

Feb 01, 2025
pulisher
Jan 30, 2025

KALA stock soars to 52-week high, reaching $8.81 - MSN

Jan 30, 2025
pulisher
Jan 28, 2025

KALA stock soars to 52-week high, reaching $8.81 By Investing.com - Investing.com Australia

Jan 28, 2025
pulisher
Jan 27, 2025

ED Attaches ₹79.78 Crore Assets In Sharon Bio-Medicine’s ₹220 Crore Bank Fraud Case - Free Press Journal

Jan 27, 2025
pulisher
Jan 21, 2025

Atara stock extends losses on FDA clinical hold (ATRA:NASDAQ) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 17, 2025

Ramesh Lal Kala , IND candidate bio : Assets , Total Income , Liabilities , Criminal Cases and other details. - The Hindu

Jan 17, 2025
pulisher
Jan 10, 2025

KALA BIO Announces $10.75 Million Private Placement Agreement - WilmerHale

Jan 10, 2025
pulisher
Jan 08, 2025

Kala Bio executive Todd Bazemore sells $15,206 in stock By Investing.com - Investing.com Australia

Jan 08, 2025

Kala Bio Inc Stock (KALA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Kala Bio Inc Stock (KALA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Brazzell Romulus K
SEE REMARKS
Jan 06 '25
Sale
7.63
2,446
18,663
92,418
Iwicki Mark T
CHIEF EXECUTIVE OFFICER
Jan 06 '25
Sale
7.63
5,779
44,094
280,076
Reumuth Mary
CHIEF FINANCIAL OFFICER
Jan 06 '25
Sale
7.63
1,706
13,017
68,581
$78.82
price down icon 3.23%
$23.07
price up icon 1.68%
$34.02
price up icon 1.11%
$20.07
price down icon 2.46%
biotechnology ONC
$244.35
price down icon 10.01%
$112.86
price down icon 0.06%
Cap:     |  Volume (24h):